Substance P (NK1) Receptor Neurons represent a specialized population of neurons expressing the NK1 receptor, the high-affinity receptor for Substance P (SP), a member of the tachykinin neuropeptide family. These neurons are widely distributed throughout the central and peripheral nervous system and play critical roles in pain transmission, neuroinflammation, mood regulation, and autonomic function. Recent research has increasingly implicated Substance P and NK1 receptor signaling in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[^1][1].
Substance P (NK1) Receptor Neurons are neurons expressing the NK1 receptor, a member of the Tachykinin receptor family (also known as TACR1). These neurons are widely distributed throughout key brain regions including the amygdala, hippocampus, basal ganglia, striatum, and spinal cord dorsal horn[2]. The NK1 receptor is a G protein-coupled receptor (GPCR) that primarily signals through Gq proteins, activating phospholipase C (PLC) and leading to downstream effects including calcium mobilization, protein kinase C (PKC) activation, and gene transcription modulation[3].
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000197 | sensory receptor cell |
| Property | Value |
|---|---|
| Receptor Type | NK1 (TACR1) |
| Family | Tachykinin (GPCR) |
| Signaling Mechanism | Gq protein-coupled, activates phospholipase C |
| Primary Ligand | Substance P (SP) |
| Primary Brain Locations | Amygdala, hippocampus, striatum, nucleus accumbens, spinal cord dorsal horn |
Substance P acts as a neuropeptide neurotransmitter and neuromodulator in the mammalian nervous system. Unlike classical amino acid neurotransmitters, Substance P is synthesized in the cell body and transported to synaptic terminals where it is released upon neuronal activation. NK1 receptor-expressing neurons participate in:
The NK1 receptor signals through Gq protein-coupled receptor activation:
This mechanism allows rapid modulatory responses depending on the cellular context and co-expression of other receptors.
Substance P and NK1 receptor signaling have been implicated in several key aspects of Alzheimer's disease pathogenesis:
In Parkinson's disease, Substance P neurons are particularly relevant due to their localization in key affected regions:
The NK1 receptor represents a potential therapeutic target for neurodegenerative diseases:
| Approach | Status | Evidence |
|---|---|---|
| NK1 antagonists | Clinical trials | Failed for depression; potential for neuroprotection |
| Substance P analogs | Preclinical | Show promise in reducing neuroinflammation |
| Gene therapy | Experimental | NK1 overexpression studies in models |
Substance P and Parkinson's disease: emerging concepts in neuron-glia interactions. Neural Plasticity. 2020. ↩︎
Distribution of NK1 ( substance P ) receptors in the human brain: an autoradiographic study. Neuroscience. 1994. ↩︎
Signal transduction mechanisms for substance P in the nervous system. Progress in Brain Research. 1991. ↩︎
Substance P and pain: an electrophysiological study in the rat spinal cord. Brain Research. 1984. ↩︎
Substance P protects against beta-amyloid-induced neuron injury. Journal of Molecular Neuroscience. 2015. ↩︎
Tachykinin NK1 receptor activation promotes neuroinflammation. Current Alzheimer Research. 2017. ↩︎
Substance P and dopaminergic neurons: implications for Parkinson's disease. Journal of Neural Transmission. 2008. ↩︎